Abstract Number: 1260 • 2012 ACR/ARHP Annual Meeting
Hydroxychloroquine Reduces the Risk of Coronary Artery Disease in Patients with Rheumatoid Arthritis
Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) can alter cardiovascular risk in RA by inflammation or by influencing cardiovascular risk factors indirectly. However, previous studies predominantly…Abstract Number: 1261 • 2012 ACR/ARHP Annual Meeting
Epicardial Adipose Tissue Is Associated with Cardiometabolic Risk and the Metabolic Syndrome in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased coronary atherosclerosis and this may be related to their increased prevalence of visceral adiposity, insulin resistance, and…Abstract Number: 1262 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients with Higher Disease Severity and Subclinical Carotid Plaque Experience More Cardiovascular Events Despite a Favorable Conventional Cadiovascular Risk Profiles
Background/Purpose: It has been shown that patients with rheumatoid arthritis (RA) experience cardiovascular (CV) events more often than expected. Increased risks of CV diseases in…Abstract Number: 1263 • 2012 ACR/ARHP Annual Meeting
Carotid Arterial Wall Inflammation Is Associated with a Specific Profile of Inflammatory Biomarkers and Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Patients
Background/Purpose: Patients with RA are at increased risk of cardiovascular (CV) comorbidity and premature mortality. While generally attributed to accelerated atherosclerosis, the pathogenesis remains poorly understood.…Abstract Number: 1264 • 2012 ACR/ARHP Annual Meeting
Vascular Age in Rheumatoid Arthritis Patients
Background/Purpose: The European League Against Rheumatism (EULAR) recommends cardiovascular risk (CV) assessment using the systematic coronary risk evaluation (SCORE) chart in rheumatoid arthritis (RA) patients.…Abstract Number: 1265 • 2012 ACR/ARHP Annual Meeting
Lipoprotein Subclass Particles and Small Vessel Elasticity As a Potential Marker for Early Atherosclerosis in Rheumatoid Arthritis: a Prospective, Controlled Study
Background/Purpose: Rheumatoid arthritis (RA) has increased rates of cardiovascular (CV) events. However, standard CV risk factors, such as routine lipid profiles, are not different in…Abstract Number: 1266 • 2012 ACR/ARHP Annual Meeting
Evaluation of Metabolic Syndrome in 97 Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an independent risk factor for cardiovascular disease (CVD), which is the leading cause of death in this group. Thus, the…Abstract Number: 1267 • 2012 ACR/ARHP Annual Meeting
Inflammatory Burden Predicts Progression of Carotid Plaque in Rheumatoid Arthritis: A 24-Month Longitudinal Analysis
Background/Purpose: Carotid atherosclerosis, which is associated with the increased risk of cardiovascular (CV) disease, is increased in rheumatoid arthritis (RA) patients. In our previous study,…Abstract Number: 1268 • 2012 ACR/ARHP Annual Meeting
Lipid Alterations and Measurement of Arterial Stiffness in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Increased arterial stiffness, an independent risk factor for premature coronary artery disease, has been reported in…Abstract Number: 1269 • 2012 ACR/ARHP Annual Meeting
Serum Cytokines Associated with Carotid Atherosclerosis in Rheumatoid Arthritis
Background/Purpose: The mechanism for the increased cardiovascular morbidity and mortality in rheumatoid arthritis (RA) is incompletely understood. In a previous analysis, we found that both…Abstract Number: 1270 • 2012 ACR/ARHP Annual Meeting
Role of Inflammation, Serologic Status and Low Density Lipoprotein in Coronary Heart Disease Among Patients with Rheumatoid Arthritis: Data From the National Veterans Health Administration
Background/Purpose: Rheumatoid arthritis (RA) increases the risk for coronary heart disease and ischemic events like myocardial infarction (MI). The association between traditional cardiovascular risk factors in…Abstract Number: 1271 • 2012 ACR/ARHP Annual Meeting
Two-Year Drug Survival and Treatment Effect of Abatacept and Tocilizumab in the Treatment of Rheumatoid Arthritis in Routine Care. Results From the Nationwide Danish Danbio Registry
Background/Purpose: Abatacept and tocilizumab have been shown to be efficacious for the treatment of rheumatoid arthritis (RA), even in patients refractory to tumor necrosis factor…Abstract Number: 1272 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Incomplete Secondary Responders to TNF-Alpha Safely Achieve Efficacy by Switching to Certolizumab Pegol in a 24-Week Study: A Phase IV, Randomized Multicenter, Double-Blind, Twelve-Week Study Followed by a 12 -Week Open-Label Phase
Background/Purpose: Certolizumab pegol (CZP), an inhibitor of TNF-alpha, has demonstrated rapid and sustained efficacy in RA patients. Switching from one anti-TNF therapy to another has…Abstract Number: 1273 • 2012 ACR/ARHP Annual Meeting
Can Response Duration After the First Rituximab Treatment Be Used in Timing of Rituximab Retreatment?
Background/Purpose: The optimal retreatment strategy for rituximab is not clear1. Different strategies are being used in clinical practice, including: on demand retreatment when disease activity…Abstract Number: 1274 • 2012 ACR/ARHP Annual Meeting
Relationship Between Morning Stiffness Duration and Severity, Pain Intensity, and Measures of Disease Activity in a 12 Week Efficacy Study of a Modified (Delayed-Release) Prednisone Plus Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Background/Purpose: RA patients typically present with pain and morning stiffness (MS). MS is predictive of both functional disability and escalated RA care, but the best…